Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: Population based cohort study

BMJ (Online)

Volumn 344, Issue 7848, 2012, Pages

  Huybrechts, K F ^a   Gerhard, T ^b   Crystal, S ^b   Olfson, M ^c   Avorn, J ^a   Levin, R ^a   Lucas, J A ^d   Schneeweiss, S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

AGED; ARTICLE; BEHAVIOR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DRUG EFFICACY; DRUG EXPOSURE; ELDERLY CARE; GERIATRIC PATIENT; HEALTH CARE PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MORTALITY; NURSING HOME; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RESIDENTIAL CARE; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES; CAUSE OF DEATH; COMORBIDITY; DOSE RESPONSE; DRUG TOXICITY; EPIDEMIOLOGY; FEMALE; MALE; MEDICAL CARE; STATISTICS;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CAUSE OF DEATH; COMORBIDITY; DEMENTIA; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; EPIDEMIOLOGIC METHODS; FEMALE; HALOPERIDOL; HUMANS; MALE; MEDICAL ASSISTANCE; MORTALITY; NURSING HOMES; RISPERIDONE; UNITED STATES;

EID: 84858419468     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e977     Document Type: Article

References (45)

1. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003;64:1106-12. (Pubitemid 37158258)
2. Briesacher BA, Limcangco MR, Simoni-Wastila L, Doshi JA, Levens SR, Shea DG, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005;165:1280-5. (Pubitemid 40989593)
3. Bronskill SE, Anderson GM, Sykora K, Wodchis WP, Gill S, Shulman KI, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 2004;52:749-55. (Pubitemid 38596494)
4. Rochon PA, Stukel TA, Bronskill SE, Gomes T, Sykora K, Wodchis WP, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007;167:676-83. (Pubitemid 46598460)
5. Chen Y, Briesacher B, Field T, Tjia J, Lau D, Gurwitz J. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010;170:89-95.
6. Beers M, Avorn J, Soumerai S, Everitt D, Sherman D, Salem S. Psychoactive medication use in intermediate-care facility residents. JAMA 1988;260:3016-20. (Pubitemid 19003116)
7. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health 1980;70:485-91. (Pubitemid 10098089)
8. Avorn J, Wang P. Drug prescribing, adverse reactions, and compliance in elderly patients. In: Salzman C, ed. Clinical geriatric psychopharmacology. 4th ed. Lippincot, Williams &Wilkins, 2005:23-47.
9. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2007;33:957-70. (Pubitemid 351367549)
10. FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. 2010. www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.
11. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005;353:2335-41. (Pubitemid 41713745)
12. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176:627-32. (Pubitemid 46426056)
13. Gill SS, Bronskill SE, Normand S-LT, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86. (Pubitemid 351650498)
14. FDA. Information for Healthcare Professionals - antipsychotics. 2011. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm.
15. Office of Inspector General, Department of Health and Human Services. Medicare atypical antipsychotic drug claims for elderly nursing home residents. Department of Health and Human Services, 2011.
16. Wang P, Brookhart M, Setoguchi S, Patrick A, Schneeweiss S. Psychotropic medication use for behavioral symptoms of dementia. Curr Neurol Neurosci Rep 2006;6:490-5. (Pubitemid 44742117)
17. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
18. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19:858-68.
19. Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull R Coll Psychiatr 1997;21:224-6. (Pubitemid 27225823)
20. Lehman A, Steinwachs D. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10. (Pubitemid 28128486)
21. Woods S. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7. (Pubitemid 36750143)
22. Sesso H, Gaziano J, Glynn R, Buring J. Value of an endpoints committee versus the use of nosologists for validating cause of death. Contemp Clin Trials 2006;27:333-9. (Pubitemid 43928878)
23. Chan Y, Pariser S, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy 1999;19:811-22. (Pubitemid 29415836)
24. Lawlor B. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psych 2004;65:5-10.
25. Maixner S, Mellow A, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psych 1999;60:29-41. (Pubitemid 29226623)
26. Tariot P. The older patient: the ongoing challenge of efficacy and tolerability. J Clin Psych 1999;60:29-33.
27. Alexopoulos G, Streim J, Carpenter D, Docherty J. Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psych 2004;65:5-99.
28. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64. (Pubitemid 33000813)
29. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002;137:693-5. (Pubitemid 35176104)
30. Robins J, Hernán M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60. (Pubitemid 30660034)
31. Schneeweiss S, Rassen J, Glynn R, Avorn J, Mogun H, Brookhart M. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-22.
32. Huybrechts K, Rothman K, Silliman R, Brookhart M, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011;183:E411-9.
33. Patorno E, Bohn R, Wahl P, Avorn J, Patrick A, Liu J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010;303:1401-9.
34. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303. (Pubitemid 43797117)
35. Liperoti R, Onder G, Landi F, Lapane K, Mor V, Bernabei R, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psych 2009;70:1340-7.
36. Rossom R, Rector T, Lederle F, Dysken M. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc 2010;58:1027-34.
37. Setoguchi S, Wang P, Brookhart M, Canning C, Kaci L, Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008;56:1644-50.
38. Maher A, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-69.
39. Huybrechts K, Brookhart A, Rothman K, Silliman R, Gerhard T, Crystal S, et al. Comparison of different approaches to confounding adjustment in a study on the effect of antipsychotic medication on mortality in older nursing home patients. Am J Epidemiol 2011;174:1089-99.
40. Andreasen N, Pressler M, Nopoulos P, Miller D, Ho B. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255-62.
41. Beck C. Psychosocial and behavioral interventions for Alzheimer's disease patients. Am J Geriatr Psychiatry 1998;6:S41-8.
42. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003;51:1305-17. (Pubitemid 37093582)
43. Camp CJ, Cohen-Mansfield J, Capesuti EA. Use of nonpharmacologic interventions among nursing home residents with dementia. Psychiatr Serv 2002;53:1397-401. (Pubitemid 35247248)
44. Cummings J. Behavioral and neuropsychiatric outcomes in Alzheimer's disease. CNS Spectr 2005;10:22-5. (Pubitemid 41784924)
45. Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution - a simulation study. Am J Epidemiol 2010;172:843-54.